Clinical Report: FDA broadens APDS treatment options

Overview

The FDA has approved leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in pediatric patients aged 4 to 11 years.

Background

Activated phosphoinositide 3-kinase delta syndrome (APDS) is a rare genetic disorder characterized by immune system dysfunction, leading to recurrent infections and potential organ enlargement. The recent FDA approval of leniolisib for younger patients expands treatment options for this condition.

Data Highlights

No numerical data available in the provided source material.

Key Findings

• The FDA approved leniolisib for pediatric patients aged 4 to 11 years with APDS.
• Leniolisib was previously approved for patients aged 12 years and older in 2023.
• Study 2201 demonstrated significant efficacy in reducing lymphadenopathy and improving naïve B-cell counts in older patients.
• Common adverse effects in younger patients include abdominal pain, respiratory tract infection, and diarrhea.
• Patients with moderate to severe liver impairment should not receive leniolisib.

Clinical Implications

Clinicians should be aware of the specific dosing and safety considerations for pediatric patients receiving leniolisib.

Conclusion

The FDA's approval of leniolisib for younger patients with APDS provides a new treatment option for this rare genetic disorder.

Related Resources & Content

1. FDA, FDA, 2023 -- FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system
2. retinal physician — DARPin Fails to Get Approval Due to Inflammation Issue
3. MDSpire News — FDA Monthly Preview: Key April Decisions to Watch
4. Retinal Physician — SUBSPECIALTY NEWS: Early anti-VEGF for DR shows no benefit, developments in gene therapy, research on IRD, and more.
5. The ASCO Post — FDA Pipeline: Breakthrough Therapy for NSCLC With Specific Mutation, Approval of Test for Cervical Cancer, and More
6. Activated PI3K Delta Syndrome - GeneReviews®
7. 2025 Inborn errors of immunity practice parameter
8. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome - PMC
9. Joenja, INN-leniolisib
10. NDA Multi-disciplinary Review and Evaluation {NDA 217759}
11. FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system | FDA
12. Study Details | NCT05438407 | Pediatric Patients Aged 4 to 11 Years With APDS | ClinicalTrials.gov